Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exscientia plc stock logo
EXAI
Exscientia
$4.84
$4.97
$3.80
$6.49
$632.93M0.83713,050 shsN/A
Alphabet Inc. stock logo
GOOG
Alphabet
$234.58
+0.8%
$195.51
$142.66
$236.13
$2.84T1.0123.95 million shs11.25 million shs
NVIDIA Corporation stock logo
NVDA
NVIDIA
$166.20
-3.2%
$172.55
$86.62
$184.48
$4.04T2.1237.51 million shs131.45 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.60
+1.7%
$5.40
$3.79
$12.36
$2.00B0.9124.15 million shs6.99 million shs
Banco Santander, S.A. stock logo
SAN
Banco Santander
$9.54
-0.5%
$8.97
$4.43
$9.82
$141.93B1.085.51 million shs1.82 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$19.39
+2.2%
$20.43
$16.60
$28.47
$1.43B1.791.15 million shs163,592 shs
Sanofi stock logo
SNY
Sanofi
$46.56
+2.7%
$48.84
$44.73
$60.12
$114.35B0.512.58 million shs3.39 million shs
Sanofi stock logo
SNYNF
Sanofi
$91.81
-7.9%
$97.34
$90.05
$122.03
N/AN/A37,888 shs92,981 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exscientia plc stock logo
EXAI
Exscientia
0.00%0.00%0.00%0.00%-2.42%
Alphabet Inc. stock logo
GOOG
Alphabet
+0.68%+9.55%+19.12%+33.01%+47.43%
NVIDIA Corporation stock logo
NVDA
NVIDIA
+0.61%-4.72%-3.70%+21.13%+61.62%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-2.38%-7.00%-18.26%-17.67%-25.90%
Banco Santander, S.A. stock logo
SAN
Banco Santander
+1.61%-0.70%+10.18%+19.37%+99.31%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-1.66%-4.00%-3.41%-22.95%-6.78%
Sanofi stock logo
SNY
Sanofi
-9.14%-9.23%-5.25%-10.18%-22.55%
Sanofi stock logo
SNYNF
Sanofi
-7.90%-7.63%-1.06%-10.86%-21.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exscientia plc stock logo
EXAI
Exscientia
$4.84
$4.97
$3.80
$6.49
$632.93M0.83713,050 shsN/A
Alphabet Inc. stock logo
GOOG
Alphabet
$234.58
+0.8%
$195.51
$142.66
$236.13
$2.84T1.0123.95 million shs11.25 million shs
NVIDIA Corporation stock logo
NVDA
NVIDIA
$166.20
-3.2%
$172.55
$86.62
$184.48
$4.04T2.1237.51 million shs131.45 million shs
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.60
+1.7%
$5.40
$3.79
$12.36
$2.00B0.9124.15 million shs6.99 million shs
Banco Santander, S.A. stock logo
SAN
Banco Santander
$9.54
-0.5%
$8.97
$4.43
$9.82
$141.93B1.085.51 million shs1.82 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$19.39
+2.2%
$20.43
$16.60
$28.47
$1.43B1.791.15 million shs163,592 shs
Sanofi stock logo
SNY
Sanofi
$46.56
+2.7%
$48.84
$44.73
$60.12
$114.35B0.512.58 million shs3.39 million shs
Sanofi stock logo
SNYNF
Sanofi
$91.81
-7.9%
$97.34
$90.05
$122.03
N/AN/A37,888 shs92,981 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exscientia plc stock logo
EXAI
Exscientia
0.00%0.00%0.00%0.00%-2.42%
Alphabet Inc. stock logo
GOOG
Alphabet
+0.68%+9.55%+19.12%+33.01%+47.43%
NVIDIA Corporation stock logo
NVDA
NVIDIA
+0.61%-4.72%-3.70%+21.13%+61.62%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-2.38%-7.00%-18.26%-17.67%-25.90%
Banco Santander, S.A. stock logo
SAN
Banco Santander
+1.61%-0.70%+10.18%+19.37%+99.31%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-1.66%-4.00%-3.41%-22.95%-6.78%
Sanofi stock logo
SNY
Sanofi
-9.14%-9.23%-5.25%-10.18%-22.55%
Sanofi stock logo
SNYNF
Sanofi
-7.90%-7.63%-1.06%-10.86%-21.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exscientia plc stock logo
EXAI
Exscientia
0.00
N/AN/AN/A
Alphabet Inc. stock logo
GOOG
Alphabet
2.77
Moderate Buy$227.56-2.99% Downside
NVIDIA Corporation stock logo
NVDA
NVIDIA
2.93
Moderate Buy$207.6924.97% Upside
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.40
Hold$7.2557.78% Upside
Banco Santander, S.A. stock logo
SAN
Banco Santander
2.50
Moderate BuyN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.67
Moderate Buy$27.8343.57% Upside
Sanofi stock logo
SNY
Sanofi
3.22
Buy$62.0033.16% Upside
Sanofi stock logo
SNYNF
Sanofi
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$215.00
9/3/2025
Alphabet Inc. stock logo
GOOG
Alphabet
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$265.00
9/3/2025
Alphabet Inc. stock logo
GOOG
Alphabet
Pivotal Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$245.00 ➝ $300.00
9/3/2025
Alphabet Inc. stock logo
GOOG
Alphabet
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$235.00 ➝ $270.00
9/3/2025
Alphabet Inc. stock logo
GOOG
Alphabet
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$232.00 ➝ $260.00
9/2/2025
Sanofi stock logo
SNY
Sanofi
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy
8/28/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$215.00 ➝ $230.00
8/28/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$200.00 ➝ $225.00
8/28/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$185.00 ➝ $225.00
8/28/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$190.00 ➝ $210.00
8/28/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$195.00 ➝ $245.00
(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exscientia plc stock logo
EXAI
Exscientia
$25.60M24.72N/AN/A$2.54 per share1.91
Alphabet Inc. stock logo
GOOG
Alphabet
$350.02B8.11$9.61 per share24.41$26.67 per share8.80
NVIDIA Corporation stock logo
NVDA
NVIDIA
$130.50B30.95$2.98 per share55.80$4.12 per share40.34
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$64.51M30.92N/AN/A$2.61 per share1.76
Banco Santander, S.A. stock logo
SAN
Banco Santander
$66.96B2.12$1.10 per share8.70$7.34 per share1.30
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M6.88N/AN/A$5.78 per share3.35
Sanofi stock logo
SNY
Sanofi
$44.46B2.57$4.97 per share9.36$33.20 per share1.40
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exscientia plc stock logo
EXAI
Exscientia
-$181.56M-$1.51N/AN/AN/A-882.09%-49.10%-33.13%N/A
Alphabet Inc. stock logo
GOOG
Alphabet
$100.12B$9.3925.0022.931.5531.12%34.31%24.88%11/4/2025 (Estimated)
NVIDIA Corporation stock logo
NVDA
NVIDIA
$72.88B$3.5147.4141.761.2452.41%101.74%70.72%11/19/2025 (Estimated)
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)
Banco Santander, S.A. stock logo
SAN
Banco Santander
$13.61B$0.9010.5910.361.0617.30%11.98%0.71%11/4/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$4.1611.199.801.1921.47%16.86%9.63%10/24/2025 (Estimated)
Sanofi stock logo
SNYNF
Sanofi
N/A$3.0829.76N/AN/AN/AN/A10/24/2025 (Estimated)

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q2 2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
$1.01$1.05+$0.04$1.08$45.65 billion$46.74 billion
8/6/2025Q2 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million
8/5/2025Q2 2025
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million
7/31/2025Q2 2025
Sanofi stock logo
SNY
Sanofi
$0.96$0.90-$0.06$1.84$9.91 billion$11.34 billion
7/30/2025Q2 2025
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.26$0.22-$0.04$0.25$17.69 billion$17.83 billion
7/23/2025Q2 2025
Alphabet Inc. stock logo
GOOG
Alphabet
$2.12$2.31+$0.19$5.12$93.67 billion$96.43 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exscientia plc stock logo
EXAI
Exscientia
N/AN/AN/AN/AN/A
Alphabet Inc. stock logo
GOOG
Alphabet
$0.840.36%N/A8.95%1 Years
NVIDIA Corporation stock logo
NVDA
NVIDIA
$0.040.02%N/A1.14%1 Years
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Banco Santander, S.A. stock logo
SAN
Banco Santander
$0.181.89%N/A20.00%N/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$1.603.44%N/A38.46%N/A
Sanofi stock logo
SNYNF
Sanofi
$2.803.05%N/A90.78%N/A

Latest SDGR, GOOG, NVDA, SAN, SNY, SNYNF, RXRX, and EXAI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/27/2025
NVIDIA Corporation stock logo
NVDA
NVIDIA
quarterly$0.010.02%9/11/20259/11/202510/2/2025
7/21/2025
Alphabet Inc. stock logo
GOOG
Alphabet
quarterly$0.210.4%9/8/20259/8/20259/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exscientia plc stock logo
EXAI
Exscientia
0.06
4.54
4.54
Alphabet Inc. stock logo
GOOG
Alphabet
0.07
1.90
1.90
NVIDIA Corporation stock logo
NVDA
NVIDIA
0.08
4.21
3.60
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.02
3.58
3.58
Banco Santander, S.A. stock logo
SAN
Banco Santander
N/A
0.26
0.26
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.30
3.30
Sanofi stock logo
SNY
Sanofi
0.19
1.27
0.94
Sanofi stock logo
SNYNF
Sanofi
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Exscientia plc stock logo
EXAI
Exscientia
41.58%
Alphabet Inc. stock logo
GOOG
Alphabet
27.26%
NVIDIA Corporation stock logo
NVDA
NVIDIA
65.27%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.19%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%
Sanofi stock logo
SNY
Sanofi
14.04%
Sanofi stock logo
SNYNF
Sanofi
30.06%

Insider Ownership

CompanyInsider Ownership
Exscientia plc stock logo
EXAI
Exscientia
16.40%
Alphabet Inc. stock logo
GOOG
Alphabet
12.99%
NVIDIA Corporation stock logo
NVDA
NVIDIA
4.17%
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
8.43%
Banco Santander, S.A. stock logo
SAN
Banco Santander
9.48%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
21.00%
Sanofi stock logo
SNY
Sanofi
1.00%
Sanofi stock logo
SNYNF
Sanofi
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Exscientia plc stock logo
EXAI
Exscientia
280130.77 million109.32 millionOptionable
Alphabet Inc. stock logo
GOOG
Alphabet
190,20012.09 billion10.52 billionOptionable
NVIDIA Corporation stock logo
NVDA
NVIDIA
36,00024.30 billion23.29 billionOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
400434.15 million397.55 millionOptionable
Banco Santander, S.A. stock logo
SAN
Banco Santander
199,95814.89 billion13.47 billionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.61 million58.15 millionOptionable
Sanofi stock logo
SNY
Sanofi
82,8782.46 billion2.43 billionOptionable
Sanofi stock logo
SNYNF
Sanofi
91,600N/AN/ANot Optionable

Recent News About These Companies

Sanofi Drops As Eczema Drug Faces Big Test
Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)
Sanofi (SNYNF) was upgraded to a Buy Rating at J.P. Morgan
DZ BANK AG Sticks to Their Buy Rating for Sanofi (SNYNF)
Deutsche Bank Sticks to Its Hold Rating for Sanofi (SNYNF)
Kepler Capital Remains a Hold on Sanofi (SNYNF)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Exscientia stock logo

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Alphabet stock logo

Alphabet NASDAQ:GOOG

$234.58 +1.92 (+0.82%)
As of 12:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.

NVIDIA stock logo

NVIDIA NASDAQ:NVDA

$166.20 -5.46 (-3.18%)
As of 12:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$4.60 +0.08 (+1.66%)
As of 12:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Banco Santander stock logo

Banco Santander NYSE:SAN

$9.54 -0.05 (-0.47%)
As of 12:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Banco Santander, S.A. provides various financial services worldwide. The company operates through Retail Banking, Santander Corporate & Investment Banking, Wealth Management & Insurance, and PagoNxt segments. It offers demand and time deposits, mutual funds, and current and savings accounts; mortgages, consumer finance, loans, and various financing solutions; and project finance, debt capital markets, global transaction banking, and corporate finance services. The company also provides asset management and private banking services; and insurance products. In addition, it offers corporate and investment banking services; and digital payment solutions. Further, it offers online banking and financial services to retail, business, institutional, corporate, private banking and university customers and clients. The company was formerly known as Banco Santander Central Hispano SA and changed its name to Banco Santander, S.A. in February 2007. Banco Santander, S.A. was founded in 1856 and is headquartered in Madrid, Spain.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$19.39 +0.42 (+2.19%)
As of 12:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Sanofi stock logo

Sanofi NASDAQ:SNY

$46.56 +1.23 (+2.71%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi stock logo

Sanofi OTCMKTS:SNYNF

$91.81 -7.87 (-7.90%)
As of 09/4/2025 02:51 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.